Sarepta Therapeutics (NASDAQ:SRPT) Stock Price Down 5.7% - Should You Sell?

Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Get Free Report) fell 5.7% during mid-day trading on Wednesday . The company traded as low as $18.08 and last traded at $17.89. 1,109,466 shares changed hands during mid-day trading, a decline of 46% from the average session volume of 2,072,889 shares. The stock had previously closed at $18.98.

Wall Street Analyst Weigh In

SRPT has been the subject of a number of recent analyst reports. Scotiabank raised Sarepta Therapeutics from a "sector perform" rating to a "sector outperform" rating and set a $80.00 price objective for the company in a research note on Friday, June 6th. Deutsche Bank Aktiengesellschaft reduced their price objective on shares of Sarepta Therapeutics from $50.00 to $25.00 and set a "hold" rating on the stock in a research report on Tuesday, June 17th. Wolfe Research assumed coverage on shares of Sarepta Therapeutics in a research note on Tuesday, June 17th. They set a "peer perform" rating for the company. Mizuho decreased their price target on shares of Sarepta Therapeutics from $85.00 to $40.00 and set an "outperform" rating on the stock in a research note on Wednesday, June 18th. Finally, Cantor Fitzgerald reiterated a "neutral" rating on shares of Sarepta Therapeutics in a research report on Monday, June 16th. One equities research analyst has rated the stock with a sell rating, thirteen have issued a hold rating and twelve have issued a buy rating to the stock. According to data from MarketBeat, Sarepta Therapeutics presently has a consensus rating of "Hold" and a consensus target price of $60.88.

Sarepta Therapeutics Stock Performance

The company has a quick ratio of 2.46, a current ratio of 4.02 and a debt-to-equity ratio of 1.00. The stock has a fifty day moving average price of $41.67 and a two-hundred day moving average price of $81.09. The company has a market capitalization of $1.74 billion, a price-to-earnings ratio of -6.60 and a beta of 0.61.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The biotechnology company reported ($3.42) earnings per share (EPS) for the quarter, missing the consensus estimate of $2.20 by ($5.62). The firm had revenue of $744.86 million for the quarter, compared to analyst estimates of $685.75 million. Sarepta Therapeutics had a negative return on equity of 14.88% and a negative net margin of 11.12%. Sarepta Therapeutics's revenue for the quarter was up 80.2% on a year-over-year basis. During the same period in the prior year, the business earned $0.73 earnings per share. As a group, analysts forecast that Sarepta Therapeutics, Inc. will post 2.67 EPS for the current fiscal year.

Hedge Funds Weigh In On Sarepta Therapeutics

Large investors have recently bought and sold shares of the stock. Exchange Traded Concepts LLC purchased a new stake in shares of Sarepta Therapeutics during the first quarter valued at approximately $479,000. GAMMA Investing LLC boosted its stake in Sarepta Therapeutics by 4,682.8% during the 1st quarter. GAMMA Investing LLC now owns 40,845 shares of the biotechnology company's stock valued at $2,607,000 after acquiring an additional 39,991 shares during the last quarter. Charles Schwab Investment Management Inc. grew its holdings in Sarepta Therapeutics by 2.0% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 623,749 shares of the biotechnology company's stock worth $75,842,000 after acquiring an additional 12,000 shares in the last quarter. Proficio Capital Partners LLC bought a new stake in shares of Sarepta Therapeutics in the 4th quarter worth about $3,829,000. Finally, PNC Financial Services Group Inc. increased its position in shares of Sarepta Therapeutics by 5.3% in the 4th quarter. PNC Financial Services Group Inc. now owns 2,891 shares of the biotechnology company's stock worth $352,000 after purchasing an additional 145 shares during the last quarter. Hedge funds and other institutional investors own 86.68% of the company's stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.